Navigation Links
EntreMed Reports Third Quarter 2008 Financial Results
Date:11/6/2008

ROCKVILLE, Md., Nov. 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported results for the three- and nine-month periods ending September 30, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Revenues for the third quarter 2008 were approximately $3,501,000 versus $3,520,000 for the comparable period a year ago. The Company reported a net loss for the third quarter of approximately ($3.4 million) or ($0.04) per share. This compares with a net loss of approximately ($3.0 million), or ($0.04) per share for the same period last year.

Revenues for the nine months ended September 30, 2008 were approximately $3,501,000 versus $3,520,000 for 2007. Reported net loss for the first nine months of 2008 was ($21.3 million), or ($0.26) per share as compared to ($18.6 million) or ($0.23) per share for 2007. As of September 30, 2008, EntreMed had cash and short-term investments of approximately $28 million.

Dane R. Saglio, EntreMed Chief Financial Officer, commented, "We have estimated that the royalty revenue from sales of Thalomid(R) for the 3rd quarter will be $3.5 million and we expect royalty revenue for the year to increase over 2007 with Celgene's acquisition of Pharmion Corporation. Research and development expenses for the third quarter declined versus the prior quarters in 2008 due in part to the decision made earlier in the year to discontinue the use of Panzem in oncology, but also impacted by a decreasing number of patients being treated with MKC-1 related to Phase 2 trials ini
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
2. EntreMed to Present at BioPartnering Europe Conference
3. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
4. EntreMed Reports Second Quarter 2008 Financial Results
5. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
6. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
7. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
8. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
11. EntreMed Announces 2008 Corporate and Clinical Program Priorities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Vienna University of Technology and the Maria Curie-Skłodowska ... semiconductor crystals into a silicon nanowire. With this ... and multi-functional processing units can be accommodated on ... results will be published in the journal ... cornerstone of future chip technology, but the research ...
(Date:7/23/2014)... 2014 Shimadzu Scientific Instruments has ... analysis system developed jointly with Ajinomoto Co. Inc. ... analyze 38 amino acids in nine minutes, drastically ... high-speed analysis utilizing a fast application-specific column and ... analytical results even under conditions with difficult samples ...
(Date:7/23/2014)... 23 de julio de 2014 ADB ... Compañía) ha anunciado hoy una asociación con Austen ... (ABIA o el Instituto), para el propósito de ... de terapia de señal bioeléctrica (el E-QURE BST ... Instituto, que tiene una importante experiencia en cicatrización ...
(Date:7/23/2014)... DuPont Pioneer announced today that Neal Gutterson, ... Agricultural Biotechnology (ABT), effective July 21, 2014. Gutterson joins ... as president, chief executive officer and board member. , ... seed and crop protection industry to this integral role ... president of DuPont Pioneer. “I am looking forward to ...
Breaking Biology Technology:A crystal wedding in the nanocosmos 2Shimadzu's New UF-Amino Station Provides High-Speed, Multi-Component Analysis of Amino Acids in Food & Beverage and Pharmaceutical Testing 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 4ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 5ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 6DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3
... data reported for the first time show that ... (golimumab) resulted in significantly greater inhibition of structural ... with active rheumatoid arthritis (RA) and active psoriatic ... with SIMPONI resulted in a statistically significant reduction ...
... Oct. 19 Encorium Group, Inc. (Nasdaq: ENCO ... provides design, development, and management capabilities for clinical trials ... pharmaceutical companies, today announced that it has completed a ... with a private investor for an aggregate purchase price ...
... ... Data Analysis in Biomarker Project , ... Basel, Switzerland (PRWEB) October 19, 2009 -- Genedata, a leading provider ... collaboration with the Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, ...
Cached Biology Technology:New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis 2New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis 3New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis 4New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis 5New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis 6New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis 7New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis 8New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis 9New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis 10New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis 11New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis 12Encorium Group, Inc. Completes $1.6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement; Ends Discussions to Sell Encorium OY 2Encorium Group, Inc. Completes $1.6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement; Ends Discussions to Sell Encorium OY 3Encorium Group, Inc. Completes $1.6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement; Ends Discussions to Sell Encorium OY 4Encorium Group, Inc. Completes $1.6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement; Ends Discussions to Sell Encorium OY 5Genedata and the Institute of Experimental Medicine, Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project 2Genedata and the Institute of Experimental Medicine, Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project 3Genedata and the Institute of Experimental Medicine, Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project 4
(Date:7/23/2014)... BOSTON , July 23, 2014 ... and threat detection, announced today it has been named ... . The Market Guide replaces Gartner,s well-known Magic Quadrant ... Gartner categorized BioCatch as one of several vendors to ... biometric analysis will become a standard feature of at ...
(Date:7/23/2014)... SUP05 will play an increasingly important role in carbon ... minimum zones expand, according to research published this week ... Sciences . , University of British Columbia researchers plumbed ... Inlet, to chart how microbial community metabolism changes as ... very detailed picture of how SUP05 a bacterial ...
(Date:7/23/2014)...   MedNet Solutions , a global life ... systems, is pleased to announce that M. ... executive with over 25 years of experience, has ... be responsible for MedNet,s day-to-day operating activities, driving ... product/service delivery.  "We welcome Clareece, ...
Breaking Biology News(10 mins):BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 2BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 3Research charts the ecological impact of microbial respiration in the oxygen-starved ocean 2MedNet Appoints Clareece West As Chief Operating Officer 2
... State University have solved a long-standing conundrum about ... way into limestone, sand grains, mussel shells, coral ... According to the lead investigator, ASU professor ... what is "at the heart of an erosive ...
... sugar may be enough to cool a hot temper, at least ... found that people who drank a glass of lemonade sweetened with ... than did people who consumed lemonade with a sugar substitute. ... simple sugar found in the bloodstream that provides energy for the ...
... 30, 2010Access to quality reproductive healthcare for women around ... human rights, freedom, equity, and right to control her ... Health in the current issue of Journal of Women,s ... Inc., explores the compelling medical, socioeconomic, and gender-based factors ...
Cached Biology News:Mystery dissolves with calcium pump discovery 2Mystery dissolves with calcium pump discovery 3Researchers find link between sugar, diabetes and aggression 2Researchers find link between sugar, diabetes and aggression 3Researchers find link between sugar, diabetes and aggression 4Ensuring the rights of women worldwide to reproductive health care 2
... Enhancing signals in immunostaining ,This solution has ... allows to get clearer signal than the ... reduce the amount of secondary antibody used ... accordingly you can have images with high ...
Anti-human VEGFR-2/KDR (Protein-A Purified) Polyclonal Antibody...
... exists predominantly as XDH which converts hypoxanthine ... plasma antioxidant. During ischemia, XDH is ... XO by oxidation of essential sulfhydryl groups ... the amino-terminus. AO has a higher ...
Anti-TNKS2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
Biology Products: